Skip to Content
Søg Menu
2.-6. juni 2023

Følg med når vi dækker ASCO 2023 | American Society of Clinical Oncology

Stay tuned

Oluf Dimitri Røe

Can we predict bladder cancer using the HUNT model?

/ Oluf Dimitri Røe
ASCO23Blærecancer Play the Video

Highlights fra ASCO 2023: Nye indsigter i luminal brystkræft

/ Bent Ejlertsen
ASCO23Brystcancer

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

/ BestPractice Nordic
ASCO23Lungecancer

Få seneste nyt fra dit speciale

Tilmeld dig og bliv opdateret, når der er nyt fra dit speciale

Tilmeld mig
Stine Bakkensen Bruun

Circulating methylated-HOXA9 tumor DNA as a biomarker in recurrent breast cancer

/ Stine Bakkensen Bruun
ASCO23Brystcancer Play the Video

NYHED | E-LÆRINGSKURSUS OM IMMUNTERAPI

Immunterapi: Undgå at overse bivirkninger

Tilmeld dig her

Abstracts og artikler fra ASCO 2022

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
HER2ASCO22Brystcancer

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
ASCO22Lymfom

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
ASCO22Nyrecancer

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
ASCO22Hudcancer

Se tidligere dækning af ASCO 2021 og 2020

Potentiel førstelinjebehandling ved avanceret renalcellecarcinom

/ BestPractice Nordic
ASCO21Nyrecancer
Woman with cancer looking at x-ray

Neoadjuvant nivolumab + kemoterapi forbedrer komplet patologisk responsrate og forkorter operationstid uanset stadie af NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21
Man at the doctor

Radioligand reducerer risikoen for progression og død for patienter med metastatisk kastrationsresistent prostatacancer

/ BestPractice Nordic
ASCO21Prostatacancer
Self Diagnosis Of Early Breast Cancer

Olaparib kan ændre klinisk praksis i adjuverende behandling af brystcancer

/ BestPractice Nordic
BrystcancerASCO21
Tværsnit af en nyre

KEYNOTE-564 viser lovende resultater for adjuverende behandling med pembrolizumab til højrisiko nyrekræft

/ BestPractice Nordic
ASCO21Nyrecancer
Lung Cancer

Bliver atezolizumab ny standard for adjuverende behandling af patienter med NSCLC?

/ BestPractice Nordic
NSCLCLungecancerASCO21
Mere

Back to top